1. Genetic mutation analysis helps drive treatment decisions primarily in what stage of non-small cell lung cancer (NSCLC)?

2. Which immune checkpoint inhibitor is currently the only immune therapy treatment approved by the United States Food and Drug Administration (FDA) for use in unresectable stage III non-small cell lung cancer (NSCLC) as consolidation therapy after concurrent chemoradiation based on the results of a large phase III study?

3. Which immune-mediated adverse effect occurs more often in stage III non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors than in other solid tumors treated with immune checkpoint inhibitors?

4. In unresectable stage III non-small cell lung cancer (NSCLC), how long should consolidation durvalumab be continued after definitive concurrent chemoradiation according to the PACIFIC trial?

5. What is the first-line treatment of choice for most severe immune-mediated adverse effects related to immune checkpoint inhibitors?

« Return to Activity